UPDATE 1-AstraZeneca hit by falling Crestor sales, shares fall

LONDON, May 18 (Reuters) - AstraZeneca's first quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.